Navigation Links
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
Date:9/17/2013

BREDA, the Netherlands, and GHENT, Belgium, September 17, 2013 /PRNewswire/ --

SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year.

ARGX-111 is a c-Met-targeting human monoclonal antibody that modulates all known mechanisms of action of the receptor. As well as best-in-class blocking of both ligand dependent and independent signalling through c-Met, ARGX-111 benefits from POTELLIGENT®-enhanced Antibody Dependent Cellular Cytotoxicity (ADCC), which drives the immune system to destroy c-Met positive tumor cells. Owing to this unique combination of therapeutic attributes, ARGX-111 has demonstrated superior therapeutic potential in both solid and hematological malignancies when compared to established biologic and small molecule-based c-Met therapies. ARGX-111  has  been shown to be safe and well-tolerated in non-human primate studies.

The Phase Ib study will enroll patients with tumors that have been pre-screened for over-expression of c-Met. Because of the known role of c-Met activation in promoting the metastatic potential of tumor cells, the study will also document the eradication of those patients' circulating tumor cells (CTCs), which are known to be precursors of advancing disease.

"ARGX-111 has all of the attributes to become the next-generation c-Met inhibitor of choice, given it combines best-in-class blockade of receptor function with enhanced ADCC. With such a compelling therapeutic profile, we are confident that ARGX-111 has the potential both to treat established tumors and to eradicate CTCs before they seed metastases," said Alain Thibault, M
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic variations ... how patients respond to treatment with pemetrexed (Alimta), the ... the full story. Click here to read the ... of Ljubljana and the Ljubljana Institute of Oncology tested ... of polymorphisms. They found that patients with genetic variations ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Institute in Woodland Hills and Oxnard, Calif., will speak next ... Rey, Calif. , The award-winning prosthodontist, international speaker and ... in one day dental procedure at 1:30 p.m. Friday, July ... 15 years ago, Dr. Jivraj said. Getting new teeth in ...
(Date:7/11/2014)... 11, 2014 BellasDress, the experienced dressmaker ... popular online suppliers when it comes to beach ... new collection of beach wedding outfits in its online ... of elegant outfits. , BellasDress has been considered ... world. According to the company’s senior spokesman, BellasDress provides ...
(Date:7/11/2014)... The International Concussion Organization is ... Best Buy Theater in Times Square, New York ... growing concussion epidemic that is plaguing athletes in ... competition. , The Symposium gathers more than a ... professional athletes and legal scholars for engaging and ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... statistically significant decline in prostate specific antigen (PSA) levels, ... issue of the Journal of the National Cancer ... was associated with a reduction in prostate cancer risk. ... examined the association between statins and PSA level. ...
... PAUL, Minn., Oct. 28 Dean Barkley,candidate for US Senate ... to fight HIV/AIDS in the US and around the world., ... candidates from,Minnesota will also agree to sign the pledge," said ... "The pledge helps,voters see who is prepared to take a ...
... (Nasdaq: AHII ) announced today that the Company ... quarter ended,September 30, 2008 on Tuesday, November 4, 2008. ... same day at 10:00 a.m.,Eastern Standard Time to discuss ... access the conference call by dialing (719) 785-1758.,Participants will ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... INDIANAPOLIS, Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced ... at the,following conferences:, -- Oppenheimer 19th Annual ... Eastern Standard Time ("EST"); and, -- 2008 ... at,9:30 a.m. Mountain Standard Time (11:30 a.m. EST)., ...
... Corporation,(NYSE: DHR ) announced that Executive Vice ... be presenting at the Goldman Sachs Global,Industrials Conference ... 2008 at,8:00 a.m. EST. The audio will be ... Corporation is a leading manufacturer of Professional,Instrumentation, Medical ...
Cached Medicine News:Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Senator Dean Barkley Pledges Action on HIV/AIDS Epidemic 2Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2
... design facilitates negotiation of the prostatic ... medium length olive Coude tip with ... latex construction provides added stiffness and ... in a variety of materials, eye ...
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a Malecot catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for pulling sutures from a vaginal incision into the suprapubic area during bladder suspension surgery. Supplied sterile in peel-open packages....
Medicine Products: